You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

ZALTRAP Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: ZALTRAP
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for ZALTRAP
Recent Clinical Trials for ZALTRAP

Identify potential brand extensions & biosimilar entrants

SponsorPhase
H. Lee Moffitt Cancer Center and Research InstitutePhase 2
Genzyme, a Sanofi CompanyPhase 2
Neonc Technologies, Inc.Phase 1/Phase 2

See all ZALTRAP clinical trials

Pharmacology for ZALTRAP
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZALTRAP Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZALTRAP Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ZALTRAP Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: ZALTRAP

Introduction

ZALTRAP (aflibercept), a biologic drug developed by Regeneron Pharmaceuticals in collaboration with Sanofi, is used primarily for the treatment of metastatic colorectal cancer. This article delves into the market dynamics and financial trajectory of ZALTRAP, highlighting its development, commercialization, and financial performance over the years.

Development and Approval

ZALTRAP is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factors (VEGF), inhibiting angiogenesis, the process of new blood vessel formation that is crucial for tumor growth. The drug was approved by the FDA in 2012 for use in combination with FOLFIRI (a chemotherapy regimen) for the treatment of patients with metastatic colorectal cancer who have previously been treated with an oxaliplatin-containing regimen[3].

Commercialization Agreement

The commercialization of ZALTRAP is governed by an amended and restated agreement between Regeneron and Sanofi. Under this agreement, Sanofi is solely responsible for the development and commercialization of ZALTRAP for cancer indications worldwide. Sanofi bears the costs of all development and commercialization activities and reimburses Regeneron for its costs. Additionally, Regeneron receives a percentage of the aggregate net sales of ZALTRAP each year[3].

Financial Performance

Revenue Generation

The financial performance of ZALTRAP is closely tied to its sales, which are reflected in the financial reports of both Regeneron and Sanofi. Regeneron records collaboration revenue from Sanofi, which includes a percentage of the net sales of ZALTRAP. For instance, in the first quarter of 2015, Regeneron recognized $14.9 million in collaboration revenue related to ZALTRAP, which included amounts previously reimbursed by Sanofi for manufacturing commercial supplies and the unamortized portion of up-front payments[3].

Quarterly and Annual Sales

While specific quarterly and annual sales figures for ZALTRAP are not detailed in recent reports, the drug's performance is part of the broader pharmaceutical sales of Sanofi and Regeneron. For example, in the context of Sanofi's overall pharmaceutical sales, the company's oncology segment, which includes ZALTRAP, contributes to the total revenue. However, the exact contribution of ZALTRAP is not isolated in these reports[1][4].

Collaboration Revenue

Regeneron's financial statements show that the company earns significant revenue from its collaborations, including the one with Sanofi for ZALTRAP. In the three and six months ended June 30, 2016, Regeneron recorded $9.3 million and $14.6 million, respectively, in other revenue primarily related to a percentage of net sales of ZALTRAP and manufacturing commercial supplies for Sanofi[3].

Market Dynamics

Competitive Landscape

The market for metastatic colorectal cancer treatments is highly competitive, with several other biologic and chemotherapeutic agents available. ZALTRAP competes with other anti-VEGF therapies and combination regimens. The competitive landscape is influenced by factors such as efficacy, safety, pricing, and reimbursement policies.

Regulatory Environment

Regulatory approvals and changes in guidelines can significantly impact the market dynamics of ZALTRAP. For instance, any updates in treatment guidelines or new approvals for competing drugs can affect its market share. The FDA's approval process and post-marketing surveillance also play a crucial role in maintaining the drug's market position.

Patient and Physician Adoption

The adoption of ZALTRAP by patients and physicians is influenced by clinical trial data, real-world evidence, and educational initiatives. Sanofi and Regeneron invest in medical education and marketing efforts to increase awareness and adoption of the drug.

Challenges and Opportunities

Generic Competition

While ZALTRAP is a biologic drug, the threat of biosimilar competition in the future could impact its sales. However, given the complexity of biologic drugs, the entry of biosimilars is often delayed compared to small molecule generics.

Expanding Indications

One of the key opportunities for ZALTRAP is the potential expansion into other cancer indications. Clinical trials exploring its use in other types of cancer could lead to new approvals and increased market share.

Collaboration and Licensing

The collaboration between Regeneron and Sanofi has been instrumental in the commercial success of ZALTRAP. Similar collaborations or licensing agreements with other companies could further expand its reach.

Financial Impact on Regeneron and Sanofi

Regeneron's Financials

For Regeneron, the collaboration revenue from ZALTRAP contributes to its overall financial performance. While the specific figures for ZALTRAP are not always detailed, the company's financial reports show significant revenue from its collaborations, which include the ZALTRAP agreement[3].

Sanofi's Financials

Sanofi's financial performance is more broadly impacted by its entire portfolio, including ZALTRAP. The company's oncology segment, which includes ZALTRAP, is part of its larger biopharma business. Sanofi's commitment to investing in R&D and its focus on becoming a pure-play biopharma company by 2030 also reflects the importance of drugs like ZALTRAP in its long-term strategy[1][4].

Key Takeaways

  • Development and Approval: ZALTRAP was approved by the FDA in 2012 for metastatic colorectal cancer.
  • Commercialization Agreement: Sanofi is responsible for development and commercialization, with Regeneron receiving a percentage of net sales.
  • Financial Performance: Revenue is generated through collaboration agreements, with Regeneron recording significant collaboration revenue.
  • Market Dynamics: The drug competes in a highly competitive market influenced by regulatory, clinical, and economic factors.
  • Challenges and Opportunities: Potential biosimilar competition and expanding indications are key factors.
  • Financial Impact: Contributes to the financial performance of both Regeneron and Sanofi.

FAQs

What is ZALTRAP used for?

ZALTRAP (aflibercept) is used for the treatment of metastatic colorectal cancer in combination with FOLFIRI chemotherapy.

Who developed ZALTRAP?

ZALTRAP was developed by Regeneron Pharmaceuticals in collaboration with Sanofi.

How is ZALTRAP commercialized?

Sanofi is solely responsible for the development and commercialization of ZALTRAP for cancer indications worldwide, with Regeneron receiving a percentage of the net sales.

What are the key challenges for ZALTRAP in the market?

Key challenges include generic and biosimilar competition, regulatory changes, and competition from other anti-VEGF therapies.

What are the potential opportunities for ZALTRAP?

Potential opportunities include expanding into other cancer indications through clinical trials and further collaborations or licensing agreements.

Sources

  1. Sanofi Q2 2024 Press Release - Sanofi.
  2. Regeneron Reports Fourth Quarter and Full Year 2021 Financial - Regeneron.
  3. REGENERON PHARMACEUTICALS, INC. - Regeneron.
  4. Press Release Q4 2023 English - Sanofi.
Last updated: 2024-12-18

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.